Mena Farag
@drmfarag.bsky.social
٣٤ ⋅ Doctor ⋅ Specialist Registrar (ST7) in Neurology 🧠 ⋅ PhD candidate @uclqsion.bsky.social — #HD-YAS https://orcid.org/0000-0002-0679-0117
Above all, I want to thank the incredible #HD-YAS participants, whose commitment, generosity and time made this work possible. As my PhD journey ends, it’s been a privilege to contribute to research bringing us closer to preventive therapies for HD, and I’m truly humbled to receive this recognition.
December 9, 2025 at 1:21 PM
Above all, I want to thank the incredible #HD-YAS participants, whose commitment, generosity and time made this work possible. As my PhD journey ends, it’s been a privilege to contribute to research bringing us closer to preventive therapies for HD, and I’m truly humbled to receive this recognition.
My heartfelt thanks go to my superb PhD supervisors (Professors Sarah Tabrizi, @rachiscahill.bsky.social and @profwild.bsky.social), my thesis committee (Professors Henrik Zetterberg and @profgeraintrees.bsky.social), collaborators and to my colleagues and friends @ucl-hd.bsky.social.
December 9, 2025 at 1:07 PM
My heartfelt thanks go to my superb PhD supervisors (Professors Sarah Tabrizi, @rachiscahill.bsky.social and @profwild.bsky.social), my thesis committee (Professors Henrik Zetterberg and @profgeraintrees.bsky.social), collaborators and to my colleagues and friends @ucl-hd.bsky.social.
For the first time, we show that baseline CSF PENK predicts longitudinal striatal atrophy and also outperforms NfL in distinguishing HD-ISS 0 vs 1, supporting CSF PENK as a striatum-specific biomarker to enrich early HD trials and inform future preventive trial design.
September 26, 2025 at 10:50 AM
For the first time, we show that baseline CSF PENK predicts longitudinal striatal atrophy and also outperforms NfL in distinguishing HD-ISS 0 vs 1, supporting CSF PENK as a striatum-specific biomarker to enrich early HD trials and inform future preventive trial design.